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Abstract 
Background: Artemisinin‑based combination therapy is recommended to treat Plasmodium falciparum worldwide, 
but observations of longer artemisinin (ART) parasite clearance times (PCTs) in Southeast Asia are widely interpreted 
as a sign of potential ART resistance. In search of an in vitro correlate of in vivo PCT after ART treatment, a ring‑stage 
survival assay (RSA) of 0–3 h parasites was developed and linked to polymorphisms in the Kelch propeller protein 
(K13). However, RSA remains a laborious process, involving heparin, Percoll gradient, and sorbitol treatments to obtain 
rings in the 0–3 h window. Here two alternative RSA protocols are presented and compared to the standard Percoll‑
based method, one highly stage‑specific and one streamlined for laboratory application.
Methods: For all protocols, P. falciparum cultures were synchronized with 5 % sorbitol treatment twice over two intra‑
erythrocytic cycles. For a filtration‑based RSA, late‑stage schizonts were passed through a 1.2 μm filter to isolate mero‑
zoites, which were incubated with uninfected erythrocytes for 45 min. The erythrocytes were then washed to remove 
lysis products and further incubated until 3 h post‑filtration. Parasites were pulsed with either 0.1 % dimethyl sulfoxide 
(DMSO) or 700 nM dihydroartemisinin in 0.1 % DMSO for 6 h, washed twice in drug‑free media, and incubated for 
66–90 h, when survival was assessed by microscopy. For a sorbitol‑only RSA, synchronized young (0–3 h) rings were 
treated with 5 % sorbitol once more prior to the assay and adjusted to 1 % parasitaemia. The drug pulse, incubation, 
and survival assessment were as described above.
Results: Ring‑stage survival of P. falciparum parasites containing either the K13 C580 or C580Y polymorphism (associ‑
ated with low and high RSA survival, respectively) were assessed by the described filtration and sorbitol‑only methods 
and produced comparable results to the reported Percoll gradient RSA. Advantages of both new methods include: 
fewer reagents, decreased time investment, and fewer procedural steps, with enhanced stage‑specificity conferred by 
the filtration method.
Conclusions: Assessing P. falciparum ART sensitivity in vitro via RSA can be streamlined and accurately evaluated 
in the laboratory by filtration or sorbitol synchronization methods, thus increasing the accessibility of the assay to 
research groups.
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Background
In accordance with the World Health Organization 
(WHO) guidelines, artemisinin-based combination ther-
apy (ACT) is now the front-line treatment for Plasmo-
dium falciparum [1]. Increased awareness of prolonged 
parasite clearance times (PCTs) following artemisinin 
(ART) treatment in the Greater Mekong subregion has 
raised concern of potential ART resistance [2–4]. Biolog-
ical studies of the PCTs and their in vitro surrogates will 
improve understanding of the mechanisms involved and 
their impact on parasite fitness [5, 6].
Unlike typical anti-malarial resistance, delayed parasite 
clearance is not associated with a substantial change in 
ART 50 % inhibitory concentrations (IC50) [3, 7, 8], evalu-
ated by exposing parasites in  vitro to serial dilutions of 
drug [9, 10]. In vitro studies have shown that response to 
anti-malarials, such as ART, is largely dependent upon 
intra-erythrocytic parasite stage, as trophozoites and 
schizonts prove highly susceptible to ART regardless of 
in vivo phenotype [11, 12]. However, ring-stage parasites 
aged 0–3  h show differential ability to survive pulses of 
ART in vitro among genetically distinct parasites [8, 13, 
14]. Accordingly, a ring-stage survival assay (RSA) was 
developed to distinguish parasite survival of an ART drug 
pulse in  vitro. Use of the RSA led to the association of 
in vitro survival, prolonged PCT, and parasite polymor-
phisms in Kelch propeller protein (K13) [15, 16]. While 
ACT is still efficacious, resistance to partner drugs and 
ART monotherapy place increasing pressure on ART 
[17], thereby necessitating efforts to investigate the devel-
oping relationship of RSAs, K13 polymorphisms, PCTs, 
and ACT anti-malarial efficacy as thoroughly as possible 
[18].
RSAs generally rely on a method using heparin, a Per-
coll gradient, and sorbitol to enrich for 0–3 h ring-stages. 
Rings are then pulsed with 700  nM dihydroartemisinin 
(DHA, active metabolite of ART) for 6  h, washed, and 
grown for 66  h, at which time survival is assessed by 
microscopy [8]. While effective, this protocol includes 
multiple steps over many hours, involving several chemi-
cal preparations and significant volumes of parasites. 
Here two alternative RSA preparations are presented: 
one focused on higher stage-specificity and another on 
increased time and resource efficiency. The first uses 
the precision of schizont filtration to isolate merozoites 
[19], which, after incubating with erythrocytes (red blood 
cells, RBCs), result in a highly synchronous 3 h ring-stage 
culture. The second uses sorbitol synchronization only 
and significantly lessens time investment, thus reduc-
ing the effort of the RSA procedure and allowing several 
assays to be done in parallel with ease. Accurately and 
efficiently assessing parasites at a specific age supports 
investigations to understand ART’s mechanism of action 
and the ability of Plasmodium to develop resistance.
Methods
Parasites
To evaluate RSA methods P. falciparum lines carrying 
the K13 propeller polymorphism C580Y, which is associ-
ated with prolonged PCT and approximately 10  % RSA 
survival [15, 16], and K13 propeller C580 lines, known 
to have less than 1 % viable parasites after RSA [8], were 
chosen. Parasite line 803 contains the K13 C580Y poly-
morphism and was isolated from a Cambodian patient 
presenting an extended PCT while treated with three 
daily oral doses of 4  mg/kg artesunate (AS) [7]. Clone 
GB4, which does not contain any polymorphisms in the 
Kelch propeller domain associated with increased PCTs 
or RSA survival (K13 C580), was isolated from Ghana 
prior to widespread use of ART in Africa [20]. Progeny 
from a genetic cross between 803 and GB4 contain-
ing either K13 C580 (clones 36F11, 46G9, 24G11, 39E5, 
and 34F5) or K13 C580Y (clones 61E8 and 76H10) were 
included in the analysis, along with the parental lines.
Culture conditions
Parasite cultures were maintained at 5  % haematocrit 
between 0.5–3.0  % parasitaemia, in complete media 
(cRPMI): RPMI-1640 (KD Medical, MD, USA) containing 
25 mM HEPES and 50 µg/mL hypoxanthine, supplemented 
with 0.21 % sodium bicarbonate, 20 mg/L gentamicin, and 
1  % Albumax II (Life Technologies, CA, USA). Cultures 
were incubated at 37  °C under a 90  % N2, 5  % CO2, and 
5  % O2 gas mixture. Erythrocytes were purchased from 
the Interstate Blood Bank (Memphis, TN, USA), passed 
through a Sepacell R-500 filter (Baxter, Deerfield, IL, USA) 
to remove leukocytes and platelets, washed, re-suspended 
in RPMI 1640 medium, and stored at 4 °C until use.
Percoll gradient ring‑stage survival assay
To perform the 0–3  h RSA protocol developed by Wit-
kowski, Amaratunga, and colleagues [8] (henceforth des-
ignated as the Percoll gradient RSA), 300  µL of packed 
parasitized RBCs containing 2–3 % mature schizonts (>10 
well-segmented nuclei) were collected from a P. falcipa-
rum culture previously synchronized twice with 5 % sorbi-
tol (Sigma-Aldrich, MO, USA) dissolved in distilled tissue 
culture-grade water (Gibco, MD, USA), 10  min, 37  °C, 
over two parasite intra-erythrocytic cycles. The parasites 
were then incubated in RPMI-1640 containing 15 U/mL 
heparin (Sigma-Aldrich), but no other supplements, for 
15 min at 37  °C. After incubation, parasites were placed 
onto a 35/65  % Percoll (GE Healthcare Life Sciences, 
Pittsburgh, PA, USA) gradient, centrifuged at 3000  rpm 
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for 10 min (966×g, Eppendorf Centrifuge 5810, rotor A-4-
81, no brake). The inter-phase band of late-stage schizonts 
was collected and incubated in media with fresh RBCs 
for 3 h, at 37 °C under 90 % N2, 5 % CO2, and 5 % O2 gas 
mixture (see Additional file  1). This gradient is slightly 
modified from the original Percoll gradient RSA, as per 
recommendation of Chanaki Amaratunga to improve 
separation (personal communication). After incubation, 
some schizonts had yet to invade; thus, parasites were 
treated with 5 % sorbitol again to remove remaining schi-
zonts and isolate 0–3 h ring-stage parasites. The parasite 
mixture was adjusted to 1  % parasitaemia in 20  µl with 
fresh packed RBCs, and suspended in 1 mL of cRPMI in 
a 24-well plate containing either 0.1 % dimethyl sulfoxide 
(DMSO, Sigma-Aldrich, St. Louis, MO, USA) or 700 nM 
DHA (Sigma-Aldrich, MO, USA) dissolved in 0.1  % 
DMSO for 6 h. After drug pulse, cells were washed twice 
with 10 mL cRPMI with 3 min centrifugation at 2500 rpm 
(671×g, 9 acceleration, 5 de-acceleration, Eppendorf Cen-
trifuge 5810, rotor A-4-81). Parasites were further incu-
bated with drug-free cRPMI for 66  h, when thin blood 
smears were prepared, methanol fixed, and stained with 
20  % Giemsa (Sigma-Aldrich, MO, USA) for 15  min for 
independent survival assessment by at least two experi-
enced microscopists. Evaluation consisted of counting the 
number of parasitized cells in an estimated 10,000 RBCs 
and comparing survival to DMSO drug-free incubation.
Filtration ring‑stage survival assay
Parasite cultures were twice synchronized with 5  % 
sorbitol over two parasite cycles and grown to 40 mL of 
5 % haematocrit cultures with at least 2 % parasitaemia. 
When the majority of parasites were late-stage schizonts, 
judged as overtly segmented and within minutes of 
bursting (Fig.  1), cultures were collected, centrifuged 
at 2500  rpm for 3  min (671×g, 9 acceleration, 5 de-
acceleration, Eppendorf Centrifuge 5810, rotor A-4-81), 
combined, and suspended in 10 mL cRPMI. After trans-
ferring to a 12 mL syringe, parasites were pushed through 
a 1.2  μm filter (Pall Corporation, Port Washington, NY, 
USA) into 200–250  µL fresh RBCs (packed cells) in 
10 mL fresh cRPMI [19]. After filtration, the mixture was 
incubated for 45 min on a plate shaker (speed 3, Boekel 
Scientific Orbritron V, model 281111), with a 90  % N2, 
5 % CO2, and 5 % O2 gas mixture at 37 °C. Cells were then 
washed with 10  mL cRPMI with 3  min centrifugation 
at 2500  rpm (671×g, 9 acceleration, 5 de-acceleration, 
Eppendorf Centrifuge 5810, rotor A-4-81) to remove 
remnants of lysed parasites and RBCs, then further incu-
bated until 3 h post-filtration. Resulting 3 h ring cultures 
of 0.07–0.15 % initial parasitaemia were adjusted to 2 % 
haematocrit in 1  mL cRPMI in a 24-well plate contain-
ing either 0.1 % DMSO or 700 nM DHA in 0.1 % DMSO 
and further incubated at 37 °C with gas conditions above 
(Fig.  2a). After 6  h incubation, cells were washed twice 
in 10 mL drug-free cRPMI, and then placed in new wells 
with 1 mL fresh cRPMI for 66 h cultivation. After incu-
bation, thin blood smears of each well were methanol 
fixed and stained with 20  % Giemsa for 15  min, coded 
for “blind” parasitaemia assessment, and counted inde-
pendently by two microscopists, with percent survival 
adjusted to the DMSO parasitaemia (by counting the 
number of parasitized cells in estimated 10,000 RBCs). 
Given the precise age necessary for survival of merozo-
ite filtration, the majority of parasites perish in the filter-
ing process. When too few parasites survive filtration, 
Fig. 1 Target morphology of segmented schizonts for filtration. a Cultures (1–2 mL packed RBCs) need to be at least 2–3 % mature schizonts for 
filtration method to work efficiently. b–d Schizont nuclei are distinct and separated prior to filtration, allowing parasites to burst upon passing 
through the filter and enter the assay as viable merozoites
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only low parasitaemias are achieved by 66 h incubation, 
even in DMSO control wells. In cases of particularly low 
DMSO parasitaemia (<0.40  %), the cultures were incu-
bated with fresh cRPMI for an additional 24 h and final 
smears were made at the 96 h time point. 
Sorbitol‑only ring‑stage survival assay
Parasite cultures were synchronized with 5  % sorbitol 
twice at exactly 46  h intervals to tighten synchronicity. 
When parasites were between very late schizonts and 
very early rings, cultures were synchronized with 5  % 
sorbitol once more to remove remaining mature forms. 
Immediately after sorbitol treatment, parasite cultures 
were adjusted to 1 % parasitaemia in 20 µL RBCs in 1 mL 
of cRPMI in a 24-well plate, with either 0.1 % DMSO or 
700 nM DHA dissolved in 0.1 % DMSO (Fig. 2b). After 
6  h incubation, cells were washed and incubated with 
drug-free cRPMI for 66 h, after which thin blood smears 
were prepared, methanol fixed, stained with 20 % Giemsa 
for 15  min and read by at least two microscopists. Per-
cent survival was calculated by counting the number of 
parasitized cells in estimated 10,000 RBCs and compar-
ing survival to that of the drug-free DMSO incubation.
Results and discussion
As shown in Fig. 3, all three methods produce compara-
ble results, distinguishing survival of parasites with K13 
C580 and C580Y. With the Percoll gradient and sorbitol-
only methods,  <1–2  % of K13 C580 parasites are viable 
after the DHA pulse, compared to 6–15 % of K13 C580Y 
parasites. With the filtration method, the ranges of sur-
vival increase, with <1–3 % of K13 C580 parasites and as 
much as 20 % of K13 C580Y parasites persisting after the 
DHA pulse. Across all three RSA methods, the distinc-
tion between high and low survival remains clear.
With all three methods producing consistent out-
comes, the methodologies can be directly compared for 
their respective benefits. Table  1 delineates the distin-
guishing features of each of the three methods. The two 
alternative methods presented here eliminate the need 
for heparin and Percoll. While the required number of 
parasitized cells is increased fivefold in the filtration pro-
tocol, it is reduced tenfold with the sorbitol-only RSA. 
The filtration RSA may include an additional 24 h incuba-
tion in the case of a low initial parasitaemia; however, in 
response to a significant burden of conducting RSAs, the 
time required to set up each assay is decreased in both 
alternative methods.
The variation observed between experiments involves 
several possible confounding factors. In the Percoll and 
sorbitol-only protocols, variation can be attributed to 
older rings and even some mature stages surviving 5  % 
sorbitol synchronization; older rings of sensitive lines 
have been shown to have decreased sensitivity, and 
mature stages of both K13 C580 and C580Y lines are 
highly sensitive to DHA in  vitro, thus potentially skew-
ing results [4, 8]. Despite the heightened stage-specific-
ity of the filtration RSA, variation between experiments 
Fig. 2 Preparations for drug pulse in filtration and sorbitol‑only 
assays. a Steps for filtration RSA are depicted. Late‑stage, segmented 
schizonts are collected, pushed through a 1.2 µm filter, incubated, 
washed, incubated again, and finally incubated with either 700 nM 
DHA in 0.1 % DMSO or 0.1 % DMSO only. b Sorbitol‑only RSA involves 
a single step. Early post‑invasion rings (approximately 3 h old) are 
collected, synchronized with sorbitol to remove remaining schizonts, 
and plated at 1 % parasitaemia with either 700 nM DHA in 0.1 % 
DMSO or 0.1 % DMSO
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remains similar to the other methods. This variation 
could occur because of invasion variability in the 66–90 h 
post-drug pulse incubation. Measuring survival 24 h after 
drug pulse would eliminate this variable; however, as the 
initial parasitaemia of the filtration method can be as low 
as 0.07  %, measuring survival prior to one or even two 
rounds of invasion can be difficult.
The large number of pyknotic forms present in the 72 h 
smears after using the Percoll or sorbitol-only methods 
may further confound results. Judgment of the viabil-
ity of the forms by microscopy introduces an additional 
level of uncertainty and room for error. However, the use 
of flow cytometry for determination of percent survival 
may help address this issue [4]. For laboratories with-
out access to flow cytometry, the filtration method eases 
microscopy assessment as no pyknotic forms are present 
in the final smears. A possible explanation based on the 
homogeneity of age distribution suggests highly sensitive 
and 3 h tightly synchronized rings may simply lyse after 
drug exposure, whereas slightly older rings present in 
Percoll or sorbitol-based methods may become pyknotic. 
These features offer confidence in the results produced 
by the filtration method, as there is less room for error 
both in the stage of the exposed parasites and in micros-
copy assessment.
Others have addressed the need for optimization 
through highly time-sensitive sorbitol synchroniza-
tions [21]. However, while the involved synchronization 
improves start times for the Percoll assay, it still requires 
large time investments with over a week of long, irregular 
hours. In contrast, the proposed alternatives decrease time 
and resource investment. With the sorbitol-only method, 
time investment per assay can be decreased to as little as 
30 min from collecting parasites to starting the drug pulse. 
Fig. 3 Comparison of results obtained with three RSA methods. The Percoll method is shown in black, the filtration method in gray, and the 
sorbitol‑only method in pattern. Across the three methods, results are consistent for each line and the distinction between sensitive and surviving 
is clear. GB4 and progeny 39E3, 34F5, 36F11, and 24G11 all contain K13 C580, while 803 and progeny 76H10 and 61E8 contain K13 C580Y. Survival of 
all K13 C580 lines is significantly less than those containing the K13 C580Y polymorphism. Values are presented in detail in Additional file 2
Table 1 Comparison of RSA protocols
a All methods require sorbitol synchronization two parasite cycles before performing RSA
Variables Percoll gradient RSA [8] Sorbitol‑only RSA Filtration RSA
Chemicals required during RSAa Heparin, percoll, sorbitol Sorbitol None
Volume of parasite culture needed ≥300 µL packed RBCs  
at 2 % parasitemia
40 µL packed RBCs at  
1 % parasitemia
≥1.5 mL packed RBCs at 2–3 % 
parasitemia
Number of steps until completion 17 10 12
Preparation time, before drug pulse 4.5 h 30 min 3 h
Total time of parasite incubation  
from drug pulse
66 h 66 h 66 or 90 h, if DMSO <0.40 % at 66 h
Stage distribution at time of  
drug pulse
80 % rings, 20 % trophozoites  
and schizonts
Mixture of young  
and older rings
3 h rings only
Presence of pyknotic parasites  
in read out
Yes Yes No
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The simpler setup of the assay allows multiple lines to be 
tested simultaneously with ease, thereby increasing the 
efficiency of the protocol even further. The 46 h spacing of 
sorbitol synchronizations is based on the specific in vitro 
cell cycle of the lines presented here and may not suit the 
cell cycles of other isolates. Individual laboratories should 
address the timing of synchronization to align with the cell 
cycles of their isolates and prevent selection of older rings 
from isolates with shorter cycles.
Apart from improving RSA stage-specificity, the poten-
tial precision of the filtration method opens the door 
to wider applications of the assay. ART’s mechanism of 
action may be related to cell stress responses and delayed 
cell cycles, investigated through time-specific drug 
pulses and carefully tracking parasite growth after ART 
exposure [14, 22]. For these assays, accurately staging 
parasites and maintaining a high level of synchronicity is 
essential. While estimates of delayed growth are possible 
through sorbitol synchronized parasites, the stage-speci-
ficity of the filtration RSA provides an accurate platform 
upon which to examine growth-related phenomenon.
Conclusions
The alternative RSA protocols described here provide 
simplicity and specificity without compromising the 
results. The filtration method provides greater stage-
specificity, thereby ensuring the age of the parasites is 
consistent across experiments. The sorbitol-only method 
provides an alternative to the original method with fewer 
chemicals, less time, and one-tenth of the parasite culture 
volume. These methods have not been tested outside the 
laboratory and thus will need to be validated against the 
Percoll gradient method in field settings. However, for 
testing laboratory adapted lines in  vitro, the alternative 
methods provide an opportunity to conduct RSAs with 
ease and efficiency, thus allowing laboratories with lim-
ited time and resources to study ART response in  vitro 
where previously impractical.
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